...
首页> 外文期刊>European review for medical and pharmacological sciences. >Combining clinical predictors to better predict for the no-reflow phenomenon
【24h】

Combining clinical predictors to better predict for the no-reflow phenomenon

机译:结合临床预测因素更好地预测无回流现象

获取原文
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVE: We aimed to determine whether the combination of a CHA2DS2-VASc score (C: Congestive Heart Failure, H: Hypertension, A2: Age ≥ 75 years, D: Diabetes mellitus, S: Stroke history, V: Vascular disease, A: Age ≥ 65 years, Sc: Sex category) and pre-percutaneous coronary intervention (PCI) thrombus load score was more sensitive at detecting the no-reflow phenomenon compared to the CHA2DS2-VASc score alone or to the thrombus load score alone in patients with acute ST-elevation myocardial infarction (STEMI) who had underwent primary PCI (PPCI). PATIENTS AND METHODS: 497 patients with acute STEMIs were divided into two groups: no-reflow group (n: 194) and control group (n: 303). The Thrombolysis In Myocardial Infarction (TIMI) flow grading and Myocardial Blush Grade (MBG) were used together to define angiographic no-reflow as TIMI flow 3 (with any MBG grade) or TIMI flow 3 with MBG 0 or 1. Successful reperfusion was defined as TIMI flow 3 with MBG 2 or 3. RESULTS: CHA2DS2-VASc score was significantly higher in the no-reflow group than in the control group (2 [1-4] vs. 1 [0-3], p 0.001]. Compared with the control group, the no-reflow group had a higher pre-PCI thrombus score (5 [4-5] vs. 4 [3-5], p = 0.001). Compared with the CHA2DS2-VASc score alone, the combined use of the pre-PCI thrombus score and the CHA2DS2-VASc score was associated with significant improvements in the ability to predict no-reflow (AUC) (0.65 vs. 0.60, p 0.05). The addition of the pre-PCI thrombus score to the CHA2DS2-VASc score was related to a significant net reclassification improvement of 6.7% (p = 0.047) and an integrated discrimination improvement of 0.036 (p 0.05). CONCLUSIONS: We have found that the combination of a CHA2DS2-VASc score and a pre-PCI thrombus load score was more sensitive in detecting the no-reflow phenomenon than only a CHA2DS2-VASc score in patients who underwent PPCIs for STEMIs.
机译:目的:我们旨在确定是否合并CHA2DS2-VASc评分(C:充血性心力衰竭,H:高血压,A2:年龄≥75岁,D:糖尿病,S:中风病史,V:血管疾病,A:年龄≥65岁,Sc:性别类别)和经皮冠状动脉介入治疗(PCI)血栓负荷评分比单独使用CHA2DS2-VASc评分或单纯血栓负荷评分对检测无返流现象更为敏感曾接受原发性PCI(PPCI)的急性ST抬高型心肌梗塞(STEMI)。患者与方法:将497例急性STEMI患者分为两组:无复流组(n:194)和对照组(n:303)。心肌梗塞溶栓(TIMI)血流分级和心肌腮红分级(MBG)一起用于定义TIMI血流<3(任何MBG分级)或TIMI血流3(MBG 0或1)时的血管造影无再流。定义为TIMB流3,MBG为2或3。结果:无回流组CHA2DS2-VASc评分显着高于对照组(2 [1-4] vs. 1 [0-3],p <0.001 ]。与对照组相比,无回流组的PCI前血栓评分更高(5 [4-5]比4 [3-5],p = 0.001),与单独的CHA2DS2-VASc评分相比,PCI前血栓评分和CHA2DS2-VASc评分的联合使用可显着提高预测无复流(AUC)的能力(0.65 vs. 0.60,p <0.05)。 PCI血栓评分达到CHA2DS2-VASc评分与净重分类明显改善6.7%(p = 0.047)和综合辨别度改善0.036(p <0.05)有关。 ONS:我们发现,对于接受STEMI的PPCI患者,CHA2DS2-VASc评分和PCI前血栓负荷评分的组合比仅CHA2DS2-VASc评分对检测无回流现象更为敏感。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号